For most of our memories, CBD was a wellness pitch running well ahead itself and the evidence backing it up. But the gap is narrowing from both directions at once. Regulators are close to authorising the first CBD food products in UK history, and the clinical evidence behind specific effects is catching up. More mature regulation now also means fewer wild claims around “curing” conditions.
If you’re browsing CBD products available online today, the shopping experience is markedly different from just a couple of years ago, and for the better.
Regulation Is Finally Catching Up (Unevenly)
So the real headline change here is the Food Standards Agency’s consultation on three applications (RP07, RP350, RP427) to authorise the first CBD food products ever permitted in Great Britain. A consultation ended in November 2025, with the decision now sitting with ministers in England, Wales and Northern Ireland. Until that happens, the FSA’s own position is very clear that no CBD food product currently has legal authorisation in the UK at all, whatever a label implies.
What the Actual Science Shows
The evidence side of things is interesting, because on the one hand, it’s been knocking down the old marketing claims a peg or two, yet any findings at all are also being celebrated, because before, it was more of a void and ambiguous.
A 2024 review on CBD and anxiety, spanning a decade, found it “may reduce anxiety with minimal adverse effects” and a double-blind trial of an oral CBD solution separately met its primary anxiety hypothesis against placebo. In other words, it likely doesn’t have a huge impact, but it helps some people, and it has minimal downside. It may not sound like it, but that’s a resounding success for CBD enthusiasts. A separate Phase 3 randomised trial of a CBD oral solution in 178 patients with mild to moderate anxiety also met its primary endpoints over 15 weeks, showing significant improvement on standardised anxiety scales compared to placebo.
On sleep, a 1,793 person randomised trial found that low-dose CBD produced a statistically significant improvement in sleep disturbance over four weeks. Though, it didn’t outperform a standard 5mg dose of melatonin tested in the same study. While it wasn’t included in the study, it’s generally considered the case that CBD has fewer side effects than melatonin.
None of this is a claim around cure. It’s a slow-but-sure way of finding legitimate results for CBD use and symptoms, even if they’re not yet authorised health claims (this has its own separate, slower regulatory process).
The Technology Making Any of This Checkable
What turns a lab claim into something checkable is the testing method behind it. High-performance liquid chromatography separates and quantifies THC and CBD without heat degrading the sample. UK labs doing that testing, more than ever, work to ISO 17025 (the standard UKAS), and certify testing laboratories generally.
On the production side, the equivalent shift is in extraction method. Supercritical CO2 extraction has largely replaced older hydrocarbon-solvent processes, since it leaves no solvent residue in the finished product and falls into the “generally recognised as safe” category. It can isolate cannabinoids with around 90% efficiency under optimal conditions, which is cleaner than the propane/butane-based extraction it’s replacing across concentrate production.
So, the CBD industry is moving ever closer to a product that has documented trials, a checkable process, and a generally more sure picture of what it can and can’t do. The combination of tightening regulation, growing clinical evidence, and improved production standards suggests that the gap between marketing claims and scientific reality will continue to narrow. For consumers, that means greater confidence in what they are buying, even if the full picture is still developing.
